- About
- Home
- Introduction
- Statistics
- Programs
- Dignet
- Gene
- GenePair
- Help & Docs
- Documents
- Help
- FAQs
- Links
- Acknowledge
- Disclaimer
- Contact Us
Gene Information
Gene symbol: TFPI
Gene name: tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor)
HGNC ID: 11760
Synonyms: EPI, TFI, TFPI1
Related Genes
| # | Gene Symbol | Number of hits |
| 1 | EPO | 1 hits |
| 2 | HBB | 1 hits |
| 3 | IDDM2 | 1 hits |
| 4 | INS | 1 hits |
| 5 | SERPINE1 | 1 hits |
| 6 | UCP1 | 1 hits |
Related Sentences
| # | PMID | Sentence |
| 1 | 7813818 | We studied tissue factor pathway inhibitor (TFPI) activity in insulin-dependent diabetes mellitus (IDDM) patients without macro-or microvascular complications, before and after intravenous administration of heparin, in comparison with age-matched control subjects. |
| 2 | 7813818 | A positive correlation between TFPI activity and glycated hemoglobin was demonstrated. |
| 3 | 16517409 | We show here that ectopic expression of very low levels of uncoupling protein 1 (UCP1) in epididymal fat (Epi) reverses both insulin and leptin resistance. |
| 4 | 16517409 | UCP1 expression in Epi improved glucose tolerance and decreased food intake in both diet-induced and genetically obese mouse models. |
| 5 | 16517409 | In contrast, UCP1 expression in Epi of leptin-receptor mutant mice did not alter food intake, though it significantly decreased blood glucose and insulin levels. |
| 6 | 17671395 | We designed a study to evaluate whether erythropoietin (EPO), given to patients on continuousambulatory peritoneal dialysis (CAPD) both with and without diabetes mellitus (DM), influences tissue factor (TF), tissue factor pathway inhibitor (TFPI) and oxidative stress (SOX). |
| 7 | 17671395 | Multivariate analysis showed that independent variables linked to TFPI levels in diabetic patients were Cu/Zn SOD, Ht and EPO dose. |
| 8 | 19337558 | The present study aimed to compare skin microvascular function, pulse wave velocity (PWV), and a variety of hemostatic markers of endothelium injury [von Willebrand factor (vWF), plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (t-PA), tissue factor pathway inhibitor (TFPI), and the soluble form of thrombomodulin (s-TM)] in patients with NIDDM. 54 patients with NIDDM and 38 sex- and age-matched controls were studied. 27 diabetics had no overt micro- and/or macrovascular complications, while the remainder had either or both. |